Skip to main content

OKYO Pharma Ltd

corporate_fare Company Profile

OKYO Pharma Ltd

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed OKYO - Latest Insights

OKYO
Apr 29, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
OKYO
Apr 07, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
OKYO
Mar 18, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
OKYO
Mar 12, 2026, 4:18 PM EDT
Filing Type: 6-K
Importance Score:
8
OKYO
Feb 23, 2026, 11:00 AM EST
Filing Type: 6-K
Importance Score:
9
OKYO
Feb 17, 2026, 8:23 AM EST
Filing Type: 424B5
Importance Score:
8
OKYO
Feb 13, 2026, 6:06 AM EST
Filing Type: 6-K
Importance Score:
8
OKYO
Feb 12, 2026, 4:14 PM EST
Filing Type: 6-K
Importance Score:
8
OKYO
Feb 10, 2026, 8:26 PM EST
Filing Type: 6-K
Importance Score:
8
OKYO
Feb 10, 2026, 8:24 PM EST
Filing Type: 424B5
Importance Score:
9
OKYO
Feb 10, 2026, 8:00 AM EST
Filing Type: 6-K
Importance Score:
8
OKYO
Feb 02, 2026, 5:22 PM EST
Filing Type: F-3
Importance Score:
9
OKYO
Jan 30, 2026, 5:15 PM EST
Filing Type: 6-K
Importance Score:
9
OKYO
Jan 30, 2026, 11:30 AM EST
Filing Type: 6-K
Importance Score:
7
OKYO
Jan 28, 2026, 7:40 AM EST
Filing Type: 6-K
Importance Score:
8
OKYO
Jan 23, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
7
OKYO
Jan 05, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
9